GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Cyclically Adjusted PS Ratio

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Cyclically Adjusted PS Ratio : 0.61 (As of Apr. 27, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Teva Pharmaceutical Industries's current share price is $13.81. Teva Pharmaceutical Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $22.78. Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio for today is 0.61.

The historical rank and industry rank for Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio or its related term are showing as below:

TEVA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.25   Med: 0.73   Max: 3.83
Current: 0.59

During the past years, Teva Pharmaceutical Industries's highest Cyclically Adjusted PS Ratio was 3.83. The lowest was 0.25. And the median was 0.73.

TEVA's Cyclically Adjusted PS Ratio is ranked better than
83.02% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs TEVA: 0.59

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Teva Pharmaceutical Industries's adjusted revenue per share data for the three months ended in Dec. 2023 was $3.983. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.78 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.36 0.31 0.38 0.46

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.37 0.32 0.45 0.46

Competitive Comparison of Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio falls into.



Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.81/22.78
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Teva Pharmaceutical Industries's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.983/129.4194*129.4194
=3.983

Current CPI (Dec. 2023) = 129.4194.

Teva Pharmaceutical Industries Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.870 99.695 7.620
201406 5.887 100.560 7.577
201409 5.875 100.428 7.571
201412 6.002 99.070 7.841
201503 5.800 99.621 7.535
201506 5.781 100.684 7.431
201509 5.595 100.392 7.213
201512 5.572 99.792 7.226
201603 5.228 100.470 6.734
201606 5.476 101.688 6.969
201609 5.653 101.861 7.182
201612 6.377 101.863 8.102
201703 5.556 102.862 6.990
201706 5.624 103.349 7.043
201709 5.523 104.136 6.864
201712 4.789 104.011 5.959
201803 4.966 105.290 6.104
201806 4.618 106.317 5.621
201809 4.449 106.507 5.406
201812 3.860 105.998 4.713
201903 3.805 107.251 4.592
201906 3.824 108.070 4.579
201909 3.748 108.329 4.478
201912 4.094 108.420 4.887
202003 3.975 108.902 4.724
202006 3.518 108.767 4.186
202009 3.630 109.815 4.278
202012 4.066 109.897 4.788
202103 3.597 111.754 4.166
202106 3.526 114.631 3.981
202109 3.504 115.734 3.918
202112 3.721 117.630 4.094
202203 3.307 121.301 3.528
202206 3.410 125.017 3.530
202209 3.213 125.227 3.321
202212 3.489 125.222 3.606
202303 3.284 127.348 3.337
202306 3.462 128.729 3.481
202309 3.392 129.860 3.381
202312 3.983 129.419 3.983

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Teva Pharmaceutical Industries  (NYSE:TEVA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Teva Pharmaceutical Industries Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX